Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial.

Zhao L, Tao F, Cheng Z, Lu Y, Liu M, Chen H, Zhang M, Yang Y, Song X, Sun Y, Ma X, Si S, Zhang H, Li X

Diabetes, obesity & metabolism6 May 2025Cited by 3 (Europe PMC)

PMID40329666DOI10.1111/dom.16439PepBankPUB-40329666

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Chinese adults with obesity or overweight, tirzepatide 10 mg reduced the predicted 10-year risk of type 2 diabetes more than placebo at week 52.
In plain wordsIn Chinese adults with obesity or overweight, tirzepatide 10 mg lowered predicted 10-year diabetes risk more than placebo.
Peptide
Tirzepatide
Outcome
DecreasePredicted 10-year T2D risk change at week 52 (10 mg vs placebo)
Study
n = 116
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg · 52 weeksAs given in this study (human).
Measurements
Difference in LS mean predicted T2D risk change
−3.2%
tirzepatide 10 mg vs placebo, week 52
Source sentences
Summary
The difference in LS mean risk change from baseline to week 52 was significant between both tirzepatide 10 mg (-3.2%, 95% confidence interval [CI]: -4.2%, -2.2%) and 15 mg (-3.4%, 95% CI: -4.4%, -2.4%) and placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis, the QDiabetes-2018 risk engine was used to calculate the 10-year predicted T2D risk at baseline, week 24 and week 52 among SURMOUNT-CN participants randomized to receive tirzepatide 10 mg, 15 mg or placebo.
Report a problemFND-4032966601
02HumanRandomized controlled trialEfficacy outcome
In Chinese adults with obesity or overweight, tirzepatide 15 mg reduced the predicted 10-year risk of type 2 diabetes more than placebo at week 52.
In plain wordsIn Chinese adults with obesity or overweight, tirzepatide 15 mg lowered predicted 10-year diabetes risk more than placebo.
Peptide
Tirzepatide
Outcome
DecreasePredicted 10-year T2D risk change at week 52 (15 mg vs placebo)
Study
n = 110
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mg · 52 weeksAs given in this study (human).
Measurements
Difference in LS mean predicted T2D risk change
−3.4%
tirzepatide 15 mg vs placebo, week 52
Source sentences
Summary
The difference in LS mean risk change from baseline to week 52 was significant between both tirzepatide 10 mg (-3.2%, 95% confidence interval [CI]: -4.2%, -2.2%) and 15 mg (-3.4%, 95% CI: -4.4%, -2.4%) and placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis, the QDiabetes-2018 risk engine was used to calculate the 10-year predicted T2D risk at baseline, week 24 and week 52 among SURMOUNT-CN participants randomized to receive tirzepatide 10 mg, 15 mg or placebo.
Report a problemFND-4032966602
03HumanRandomized controlled trialEfficacy outcome
In Chinese adults with obesity or overweight, the LS mean predicted 10-year T2D risk fell from baseline to week 52 with tirzepatide 10 mg.
In plain wordsIn Chinese adults with obesity or overweight, predicted 10-year diabetes risk fell over 52 weeks with tirzepatide 10 mg.
Peptide
Tirzepatide
Outcome
DecreasePredicted 10-year T2D risk from baseline to week 52 (10 mg)
Study
n = 59
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg · 52 weeksAs given in this study (human).
Measurements
Predicted T2D risk, baseline
5.3%
tirzepatide 10 mg
Predicted T2D risk, week 52
1.2%
tirzepatide 10 mg
Source sentences
Summary
from 5.3% to 1.2% for tirzepatide 10 mg
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis, the QDiabetes-2018 risk engine was used to calculate the 10-year predicted T2D risk at baseline, week 24 and week 52 among SURMOUNT-CN participants randomized to receive tirzepatide 10 mg, 15 mg or placebo.
Report a problemFND-4032966603
04HumanRandomized controlled trialEfficacy outcome
In Chinese adults with obesity or overweight, the LS mean predicted 10-year T2D risk fell from baseline to week 52 with tirzepatide 15 mg.
In plain wordsIn Chinese adults with obesity or overweight, predicted 10-year diabetes risk fell over 52 weeks with tirzepatide 15 mg.
Peptide
Tirzepatide
Outcome
DecreasePredicted 10-year T2D risk from baseline to week 52 (15 mg)
Study
n = 53
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mg · 52 weeksAs given in this study (human).
Measurements
Predicted T2D risk, baseline
4.9%
tirzepatide 15 mg
Predicted T2D risk, week 52
1%
tirzepatide 15 mg
Source sentences
Summary
from 4.9% to 1.0% for tirzepatide 15 mg
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis, the QDiabetes-2018 risk engine was used to calculate the 10-year predicted T2D risk at baseline, week 24 and week 52 among SURMOUNT-CN participants randomized to receive tirzepatide 10 mg, 15 mg or placebo.
Report a problemFND-4032966604
05HumanRandomized controlled trialEfficacy outcome
In Chinese adults with obesity or overweight, tirzepatide reduced predicted T2D risk more than placebo in all baseline BMI and prediabetes subgroups.
In plain wordsIn Chinese adults with obesity or overweight, tirzepatide lowered predicted diabetes risk more than placebo in every subgroup studied.
Peptide
Tirzepatide
Outcome
DecreasePredicted T2D risk reduction in BMI and prediabetes subgroups
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg or 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
Significantly greater predicted risk reductions for tirzepatide than placebo were observed in all subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
Subgroup analyses were conducted by baseline body weight mass index (BMI) status and baseline prediabetes status.
Summary · context
In this post hoc analysis, the QDiabetes-2018 risk engine was used to calculate the 10-year predicted T2D risk at baseline, week 24 and week 52 among SURMOUNT-CN participants randomized to receive tirzepatide 10 mg, 15 mg or placebo.
Report a problemFND-4032966605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial.

Summary

Results from this study5

Version history

Subjects

Publication types

MeSH terms

Keywords